Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 581 to 590 of 1136 total matches.
Telotristat Ethyl (Xermelo) for Carcinoid Syndrome Diarrhea
The Medical Letter on Drugs and Therapeutics • Jul 17, 2017 (Issue 1525)
with intestinal perforation.
DRUG INTERACTIONS — Simultaneous administration
of a 200-mcg dose of short-acting ...
The FDA has approved telotristat ethyl (Xermelo –
Lexicon), a tryptophan hydroxylase inhibitor, for
use in combination with a somatostatin analog
(SSA) for treatment of carcinoid syndrome diarrhea
inadequately controlled with SSA therapy alone.
Telotristat ethyl is the first oral drug to be approved
in the US for this indication.
In Brief: Zanubrutinib (Brukinsa) for CLL or SLL (online only)
The Medical Letter on Drugs and Therapeutics • Feb 20, 2023 (Issue 1670)
have occurred with use of BTK inhibitors.
DRUG INTERACTIONS — Zanubrutinib is a substrate
of CYP3A ...
The Bruton's tyrosine kinase (BTK) inhibitor
zanubrutinib (Brukinsa), which was previously
approved by the FDA for treatment of mantle cell
lymphoma, Waldenström's macroglobulinemia,
and relapsed or refractory marginal zone
lymphoma, has now been approved for treatment
of chronic lymphocytic leukemia (CLL) or small
lymphocytic lymphoma (SLL) in adults. The BTK
inhibitors ibrutinib (Imbruvica) and acalabrutinib
(Calquence) were approved earlier for treatment of
CLL and SLL.
Med Lett Drugs Ther. 2023 Feb 20;65(1670):e33-4 doi:10.58347/tml.2023.1670e | Show Introduction Hide Introduction
Valoctocogene Roxaparvovec (Roctavian) – A Gene Therapy for Severe Hemophilia A
The Medical Letter on Drugs and Therapeutics • Oct 02, 2023 (Issue 1686)
; no
malignancies have been reported to date with use of
valoctocogene roxaparvovec.
DRUG INTERACTIONS — Drugs ...
Valoctocogene roxaparvovec-rvox (Roctavian –
Biomarin), an adeno-associated virus (AAV) vector-based
gene therapy, has been approved by the FDA
for one-time treatment of severe hemophilia A
in adults without pre-existing antibodies to AAV
serotype 5. It is the first gene therapy to be approved
in the US for treatment of hemophilia A.
Med Lett Drugs Ther. 2023 Oct 2;65(1686):157-8 doi:10.58347/tml.2023.1686c | Show Introduction Hide Introduction
Pioglitazone/Metformin (Actoplus met)
The Medical Letter on Drugs and Therapeutics • Jan 30, 2006 (Issue 1227)
INTERACTIONS — Specific pharmacokinetic
drug interaction studies have not been conducted with
the new ...
For patients with diabetes poorly controlled with a single oral drug, addition of a second drug with a different mechanism can be helpful. A fixed-dose combination (Actoplus met - Takeda) of two widely used antihyperglycemic drugs, the thiazolidinedione pioglitazone (Actos) and the biguanide metformin (Glucophage, and others), has been approved by the FDA for management of type 2 diabetes. It is indicated for patients already being treated with both pioglitazone and metformin or as second-line therapy for those not adequately controlled with either metformin or pioglitazone alone....
Posaconazole (Noxafil) for Invasive Fungal Infections
The Medical Letter on Drugs and Therapeutics • Nov 20, 2006 (Issue 1248)
was used
for >6 months.
17
DRUG INTERACTIONS — Posaconazole is an
inhibitor of CYP3A4
18 ...
Posaconazole (Noxafil - Schering-Plough), an oral azole antifungal with a chemical structure similar to that of itraconazole (Sporanox), has been approved by the FDA to prevent Candida and Aspergillus infections in severely immunocompromised patients and for treatment of oropharyngeal candidiasis. It is likely also to be used off-label for treatment of other fungal infections, including those caused by Mucor and other Zygomycetes.
In Brief: A New Breast Cancer Indication for Sacituzumab Govitecan (Trodelvy) (online only)
The Medical Letter on Drugs and Therapeutics • Mar 06, 2023 (Issue 1671)
%),
alopecia (48%), hyperglycemia (37%), constipation
(34%), and decreased albumin levels (32%).
DRUG ...
Sacituzumab govitecan-hziy (Trodelvy – Gilead) has
been approved for treatment of unresectable locally
advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2
(HER2)-negative breast cancer in adults who received
prior endocrine therapy and ≥2 additional systemic
therapies for metastatic disease. It was previously
approved for treatment-refractory metastatic triplenegative
breast cancer and for treatment of locally
advanced or metastatic urothelial cancer in adults
who received platinum-based chemotherapy and a
programmed death receptor-1...
Med Lett Drugs Ther. 2023 Mar 6;65(1671):e43-4 doi:10.58347/tml.2023.1671g | Show Introduction Hide Introduction
Vorasidenib (Voranigo) for Low-Grade Glioma (online only)
The Medical Letter on Drugs and Therapeutics • Nov 11, 2024 (Issue 1715)
treatment and for 2 months after the last dose.
DRUG INTERACTIONS ― Vorasidenib is metabolized
primarily ...
The FDA has approved vorasidenib (Voranigo –
Servier), an oral isocitrate dehydrogenase (IDH)
inhibitor, for treatment of grade 2 astrocytoma or
oligodendroglioma in patients ≥12 years old with
an IDH1 or IDH2 mutation. It is the first systemic
treatment to be approved in the US for this indication.
Med Lett Drugs Ther. 2024 Nov 11;66(1715):e188-9 doi:10.58347/tml.2024.1715g | Show Introduction Hide Introduction
Biktarvy - Another INSTI-Based Combination for HIV
The Medical Letter on Drugs and Therapeutics • Aug 13, 2018 (Issue 1553)
toxicity and drug interactions,
eliminate food requirements, or reduce cost.4
CLINICAL STUDIES — Approval ...
The FDA has approved Biktarvy (Gilead), a once-daily,
fixed-dose combination of bictegravir, a new integrase
strand transfer inhibitor (INSTI), and the nucleoside
reverse transcriptase inhibitors (NRTIs) emtricitabine
and tenofovir alafenamide (TAF), for treatment of HIV-1
infection in adults. The new combination is indicated for
use in patients who are antiretroviral-naive or who have
been virologically suppressed on a stable antiretroviral
regimen for ≥3 months with no history of treatment
failure and no known substitutions associated with
resistance to any component of the...
Elexacaftor/Tezacaftor/Ivacaftor (Trikafta) for Cystic Fibrosis
The Medical Letter on Drugs and Therapeutics • Jan 13, 2020 (Issue 1589)
5%). Small increases in
blood pressure were reported with the combination.
DRUG INTERACTIONS ...
The FDA has approved Trikafta (Vertex), a fixed-dose
combination of the cystic fibrosis transmembrane
conductance regulator (CFTR) modulators elexacaftor,
tezacaftor, and ivacaftor, for oral treatment of cystic
fibrosis (CF) in patients ≥12 years old who have at
least one Phe508del mutation in the CFTR gene. About
90% of patients with CF have at least one copy of the
Phe508del (also called F508del) mutation. This is the
first approval for elexacaftor. Ivacaftor is available
alone (Kalydeco) and in 2-drug combinations with
tezacaftor (Symdeco) and lumacaftor...
Ibrexafungerp (Brexafemme) for Vulvovaginal Candidiasis
The Medical Letter on Drugs and Therapeutics • Sep 06, 2021 (Issue 1632)
of either ibrexafungerp
142
The Medical Letter ® Vol. 63 (1632) September 6, 2021
DRUG INTERACTIONS ...
The FDA has approved ibrexafungerp (Brexafemme –
Scynexis), a first-in-class triterpenoid antifungal
("fungerp"), for oral treatment of vulvovaginal candidiasis
in postmenarchal females.